Abbott (NYSE:ABT) today shared a number of positive updates on its Diabetes business as part of its second-quarter earnings report. The medtech giant’s Diabetes unit brought in sales of $1.4 billion in the quarter, marking 19.4% growth year-over-year. Its FreeStyle Libre continuous glucose monitors (CGMs) continue to drive growth as CEO Robert Ford projected earlier […]
8 drug delivery innovations you should know
Innovations in drug delivery never stop, and over the past 12 months or so a wide variety have been in the spotlight. Constant progress continues in the diabetes space, both in the form of insulin delivery and other drug delivery methods. Elsewhere, we see implants, patches, syringes and more showcasing the many ways we can […]
Ascensia Diabetes Care inks deal to integrate blood glucose monitors in point-of-care testing
Avricore Health and Ascensia Diabetes Care announced a partnership to integrate blood glucose monitoring into point-of-care testing. The deal aims to integrate the Contour Next-Gen and Contour Next One BGM systems into Avricore’s HealthTab PCOT platform. Both companies have the objective of supporting patients and pharmacists in Canada to better manage diabetes. The companies believe […]
Eitan Medical appoints new CFO
Drug delivery technology developer Eitan Medical announced today that it appointed Shaul Sharoni as its new chief financial officer. Sharoni brings more than 20 years of experience in financial management to the Netanya, Israel-based company. As CFO, his duties include overseeing all financial operations. That includes strategic financial planning, budgeting, forecasting and financial reporting. According […]
This biodegradable brain implant delivers cancer-treating drugs
Researchers say they developed a biodegradable brain implant capable of helping to deliver chemotherapy drugs directly to tumors. Medscape News reported that the research marks another step toward using ultrasound to combat cancer. According to the team, led by Thanh Nguyen, these drugs can penetrate the blood-brain barrier to reach these brain tumors. Nguyen serves […]
BD discloses 8 cybersecurity vulnerabilities with Alaris infusion system
BD (NYSE:BDX) today voluntarily posted a product security bulletin for a number of vulnerabilities with its Alaris infusion system. Franklin Lakes, New Jersey-based BD recently identified eight vulnerabilities. These vulnerabilities are associated with the BD Alaris system with Guardrails Suite MX, versions 12.1.3 and earlier. The company discovered the vulnerabilities through routine internal security testing […]
FDA approves drug-coated balloon for BPH symptoms from Urotronic
Urotronic announced that the FDA approved its Optilume BPH catheter system for to alleviate urinary symptoms caused by BPH. Minneapolis-based Urotronic designed Optilume as a minimally invasive surgical therapy. It combines mechanical dilation using a proprietary double-lobe balloon with concurrent localized delivery of paclitaxel. This treats lower urinary tract symptoms secondary to BPG (benign prostatic […]
Eitan Medical launches cloud-based infusion management platform
Drug delivery technology developer Eitan Medical announced today that it launched the Eitan Insights cloud-based infusion management system. Netanya, Israel-based Eitan Medical designed Eitan Insights to meet the unique needs of at-home and specialty infusions. The company’s infusion systems, Sapphire, and Avoset, connect and transmit infusion data to the platform. Sapphire now features a plug-and-play […]
FDA updates guidance on paclitaxel-coated devices, determines no link to late mortality risk
The FDA issued healthcare providers updated guidance for certain warning language with paclitaxel-coated devices that treat PAD. These peripheral arterial disease (PAD)-treating devices produced data that does not support an excess mortality risk. Specifically, the FDA’s guidance eliminates the need for certain warning language in the device labeling. An FDA panel in 2019 determined that […]
Better Therapeutics wins FDA nod for type 2 diabetes digital therapeutic
Better Therapeutics (Nasdaq:BTTX) announced that the FDA authorized its AspyreRx prescription digital therapeutic for diabetes. AspyreRx, formerly BT-001, provides cognitive behavioral therapy to patients 18 years or older with type 2 diabetes. The prescription-only digital therapeutic (PDT) underwent review through the FDA de novo pathway. The company submitted an FDA de novo request in September 2022 for […]